KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBT Margin (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of EBT Margin data on record, last reported at 4721.69% in Q4 2025.

  • For Q4 2025, EBT Margin rose 476922.0% year-over-year to 4721.69%; the TTM value through Dec 2025 reached 67.6%, up 2839.0%, while the annual FY2025 figure was 2199.06%, 226439.0% up from the prior year.
  • EBT Margin reached 4721.69% in Q4 2025 per IONS's latest filing, up from 81.93% in the prior quarter.
  • Across five years, EBT Margin topped out at 4721.69% in Q4 2025 and bottomed at 220666.67% in Q2 2024.
  • Average EBT Margin over 5 years is 10924.31%, with a median of 70.47% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -22062556bps in 2024, then skyrocketed 22071110bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 424.8% in 2021, then plummeted by -107bps to 29.19% in 2022, then soared by 450bps to 102.29% in 2023, then tumbled by -146bps to 47.53% in 2024, then surged by 10035bps to 4721.69% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 4721.69% in Q4 2025, 81.93% in Q3 2025, and 44.44% in Q2 2025.